Established in 2004, Avivia is a specialized pharmaceutical development company engaged in CRO service activities, drug repositioning, repurposing and reformulation. Over the past ten years, the company has built a solid reputation recognized for its R&D flexibility and ‘out-of-the-box’ approach towards complex and challenging analytical and pharmaceutical development projects. Today, we are the preferred partner for many big pharma, specialty pharma, generic drug companies and smaller drug development firms. We operate a hybrid business model combining CRO service activities (both full development programs as well as stand-alone services) with internal product programs aimed at the development of value-added products. Our offices and state-of-the-art laboratories are located in Nijmegen, The Netherlands, in close proximity to the German and Belgian borders.


The Avivia management team combines the experiences of executives and a top-tier advisory board with extensive backgrounds in managing, developing and exiting successful businesses in the pharmaceutical and generics industry.

Johannes (‘Hans’) J. Platteeuw

Johannes (‘Hans’) J. Platteeuw - Founder & CEO

Mr. Platteeuw holds a master’s degree in Chemistry from the University of Nijmegen, The Netherlands. He started his career at Synthon BV as Project Manager of pharmaceutical product development and later became the company’s Head of Galenical R&D. In this latter position, Mr. Platteeuw contributed to the development of Synthon’s R&D organization and product portfolio, including the granting of 10 worldwide patents. In 2004 he moved to Dafra Pharma, a private company specialized in antimalarial medication where he acted as Director R&D and was instrumental for the launch of Co-Arinate which provided an effective treatment of malaria within 24 hours and which ever since has been the top selling product of Dafra. In 2005, he started Avivia BV, an independent company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products. Through Avivia he has been hired by many companies in roles as project manager (Disphar, Organon/SP, Pharming, Virostatics, Genetic Immunity, Metaptys), chief operating officer (Formac Pharmaceuticals), chief development officer (Chamaeleo) or director pharmaceutical R&D (Pantarhei). For most of these companies his work resulted in further patent applications (15), licensing deals and significant market revenue.

Menno Wiltink

Menno Wiltink - Project Leader and Head of Analytical R&D

Mr. Wiltink is a Partner in Avivia who has 25 years of experience in the pharmaceutical R&D with expertise in Analytical Research and Support, API, Excipient and Drug Product Characterization and Troubleshooting, Predictive Dissolution Testing, Preclinical Evaluation and Equivalence selection. He was Head Analytical Development at Synthon BV and studied Analytical Sciences at the University in Amsterdam and Environmental Analysis at the Van Hall Larenstein, University of Applied Sciences.

Dennie van den Heuvel

Dennie van den Heuvel - Project Leader and Head of Pharmaceutical R&D

Mr. van den Heuvel is a Partner in Avivia who has over 20 years working experience in the pharmaceutical industry and is an expert in formulation development. Related topics range from preclinical development up to the market formulation including production, IP and regulatory requirements. He held different positions at Intervet/Akzo-Nobel and Synthon and has extensive experience in project management, working in and leading/coaching interdisciplinary teams (CMC, Toxicology, Clinical, Regulatory, Analytics). He is an inventor of 25+ patents in name of Synthon.

Hans van der Steen

Hans van der Steen - Project Leader and Manager of Operations

Mr. van der Steen holds a bachelor's degree in analytical chemistry from the Fontys higher education of Eindhoven. After obtaining more than 10 years of experience in analytical chemistry in the pharmaceutical and excipient industry, Organon NV, CP Kelco and Synthon biologicals, he joined Avivia in 2015. His area of interest and expertise includes API and excipient characterisation, analytical research & support and drug product troubleshooting & development. Apart from acting as a Project Leader, he is responsible for managing the practical work in our analytical lab.

Marleen De Vriese

Marleen De Vriese - Project Leader and Manager of Operations

Mrs. De Vriese is a Master in Biomedical Sciences graduated from the University of Antwerp (Belgium) with over 15 years of experience in managing pharmaceutical development projects at Dafra Pharmaceuticals, Formac and Avivia. Within Avivia Mrs. De Vriese’s focus is in the daily follow up of the in house development programs.

Frank Vanderdonck

Frank Vanderdonck - Advisor, Business intelligence & Medical Strategy

Mr. Vanderdonck has over 12 years of experience in various roles in the pharmaceutical industry, mainly focusing on urology, oncology, neurology and immunology areas. Prior to joining Avivia, he worked in the Medical Affairs and Clinical Research teams for Ipsen and Pfizer. At UCB, he led global Medical Science Liaison initiatives and was Associate Director of Business Intelligence in the Portfolio Management and New Product Planning team, subsequently leading the Competitive Intelligence efforts in the Global Strategic Marketing group. At Heartbeat Software he co-founded the services team, leading the project, medical strategy and software implementation for major pharma companies such as Roche, GSK and Boehringer Ingelheim. Mr. Vanderdonck received a Masters of Pharmaceutical Sciences from the University of Ghent (Ghent, Belgium) and is an Academy of Competitive Intelligence graduate as well as a Certified Marketing Manager.

Laurens G. Theunis

Laurens G. Theunis - Advisor, Business Development & Investments

Mr. Theunis is a biotech and pharma professional with over 16 years of experience in the industry. He is the co-founder of TEDS (image-guided cancer surgery initiative), FORMAC Pharmaceuticals NV (drug delivery and development company), CellVir Pharmaceuticals NV (HIV drug discovery and development firm) and Chamaeleo Pharma (oncology pharma company). Mr. Theunis is also a member of the Strategic Advisory Board of ModiQuest Research BV (antibody services, discovery and development company). He started his career at Galapagos NV (drug development) as a Manager of Business Development, responsible for the Company’s service unit. Mr. Theunis holds a Master’s of Science Degree in Bio-engineering from the University of Ghent (Ghent, Belgium) and ENSAM (Montpellier, France), and a Master Degree in Finance from the Solvay Business School (Brussels, Belgium).

Wout Wouters

Wout Wouters - Chief Operating Officer

After obtaining a PhD in Pharmacology in 1979, Mr. Wouters started his professional career at Solvay Pharmaceuticals, where he held several positions among others Head of the Department of Pharmacology. Therapeutic areas of interest were Cardiovascular, CNS and Women's Health. In 1999 he joined the Dutch Institute of Applied Research (TNO). Since 2010, Wout has been part of the Avivia team as an independent Pharmaceutical Professional.

Rianne Visser

Rianne Visser - Junior Scientist Pharmaceutical Development

Ms. Visser holds a master’s degree in Molecular Life Sciences from the Radboud University of Nijmegen, The Netherlands.
Within Aviva, she supports our Analytical and Pharmaceutical R&D team. Her focus lays in Research and Support, and practical work in our Pharmaceutical and Analytical lab.

Marcel Langoor

Marcel Langoor - Business Development

Mr. Langoor holds a PhD degree in chemistry from the University of Utrecht (1997). After a few years in the bulk chemicals industry in various roles with increasing responsibility, in 2003 he moved to the life sciences sector by working for the contract laboratory PROXY Laboratories in Leiden as Director Business Development. After completion of a management buy out in 2012 the company’s organic growth was accelerated through M&A activities. Early 2016 all acquired companies were sold to Eurofins BioPharma Product Testing (EBPT). Until the end of 2018 Mr Langoor was Director BD of EBPT Netherlands and Project Leader Biologicals for the global EBPT group. During his 16 years tenure Mr Langoor has worked with hundreds of clients ranging from big pharma to biotech startups, from small molecules (innovator and generic) to biologicals (innovator and biosimilar), worldwide.


Avivia is growing so we are constantly looking for Junior and Senior Scientists (Pharmaceutical Development) to join our team and to help us achieve our goals.  We are keen on people who say what they’ll do and do it, are 100% focused on results and success, have a strong personality (but not too strong), and want to work in pharma for the right reasons.  If you are interested to join our team, don’t hesitate to let us know. Get in touch.


At Avivia we are proud of our development facilities and equipment, which enable us to perform formulation and analytical R&D at the highest level. A recent upgrade and expansion of the facilities provides even more flexibility and increased capacity of our services. We welcome all interested parties to visit us for a tour through our state-of-the-art facilities!

Avivia office NovioTech Campus Nijmegen Netherlands
Avivia Equipment LC with Empower 3
Avivia pharmaceutical research laboratory capabilities
Avivia USP III BioDis reciprocating cylinder, dissolution tester
Avivia Office & R&D Facilities ↓

Contact Avivia ►

Avivia BV M-building – Novio Tech Campus
Transistorweg 5
6534 AT Nijmegen, The Netherlands

Email info [at] avivia.nl

Phone - Reception +31 (0)6-1968-6732